Dr Reddy's Laboratories Current Ratio 2012-2025 | RDY
Current and historical current ratio for Dr Reddy's Laboratories (RDY) from 2012 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Dr Reddy's Laboratories current ratio for the three months ending December 31, 2025 was 1.88.
| Dr Reddy's Laboratories Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-12-31 | $3.31B | $1.76B | 1.88 |
| 2025-09-30 | $3.15B | $1.70B | 1.85 |
| 2025-06-30 | $3.15B | $1.66B | 1.89 |
| 2025-03-31 | $2.93B | $1.53B | 1.92 |
| 2024-12-31 | $2.96B | $1.54B | 1.92 |
| 2024-09-30 | $2.96B | $1.54B | 1.92 |
| 2024-06-30 | $3.23B | $1.27B | 2.55 |
| 2024-03-31 | $2.98B | $1.15B | 2.58 |
| 2023-12-31 | $2.87B | $1.13B | 2.55 |
| 2023-09-30 | $2.62B | $1.01B | 2.59 |
| 2023-06-30 | $2.56B | $0.98B | 2.60 |
| 2023-03-31 | $2.52B | $1.04B | 2.41 |
| 2022-12-31 | $2.35B | $1.02B | 2.31 |
| 2022-09-30 | $2.16B | $0.98B | 2.19 |
| 2022-06-30 | $2.27B | $1.15B | 1.98 |
| 2022-03-31 | $2.40B | $1.24B | 1.94 |
| 2021-12-31 | $2.24B | $1.13B | 1.99 |
| 2021-09-30 | $2.20B | $1.16B | 1.90 |
| 2021-06-30 | $2.14B | $1.23B | 1.74 |
| 2021-03-31 | $2.03B | $1.14B | 1.78 |
| 2020-12-31 | $1.83B | $1.01B | 1.81 |
| 2020-09-30 | $1.84B | $1.07B | 1.72 |
| 2020-06-30 | $1.76B | $1.06B | 1.66 |
| 2020-03-31 | $1.73B | $0.97B | 1.79 |
| 2019-12-31 | $1.64B | $0.91B | 1.81 |
| 2019-09-30 | $1.70B | $0.87B | 1.96 |
| 2019-06-30 | $1.68B | $0.89B | 1.90 |
| 2019-03-31 | $1.66B | $0.86B | 1.92 |
| 2018-12-31 | $1.62B | $0.90B | 1.81 |
| 2018-09-30 | $1.59B | $0.98B | 1.62 |
| 2018-06-30 | $1.68B | $1.03B | 1.64 |
| 2018-03-31 | $1.68B | $1.07B | 1.57 |
| 2017-12-31 | $1.72B | $1.15B | 1.50 |
| 2017-09-30 | $1.58B | $1.08B | 1.46 |
| 2017-06-30 | $1.55B | $1.01B | 1.53 |
| 2017-03-31 | $1.55B | $1.31B | 1.18 |
| 2016-12-31 | $1.55B | $1.40B | 1.11 |
| 2016-09-30 | $1.50B | $1.34B | 1.12 |
| 2016-06-30 | $1.51B | $1.00B | 1.52 |
| 2016-03-31 | $1.81B | $0.98B | 1.85 |
| 2015-12-31 | $1.80B | $0.96B | 1.89 |
| 2015-09-30 | $1.77B | $1.00B | 1.77 |
| 2015-06-30 | $1.82B | $1.02B | 1.79 |
| 2015-03-31 | $1.92B | $1.03B | 1.87 |
| 2014-12-31 | $1.77B | $0.93B | 1.91 |
| 2014-09-30 | $1.73B | $0.88B | 1.96 |
| 2014-06-30 | $1.76B | $0.88B | 2.00 |
| 2014-03-31 | $1.73B | $0.90B | 1.92 |
| 2013-12-31 | $1.65B | $0.91B | 1.80 |
| 2013-09-30 | $1.55B | $0.88B | 1.77 |
| 2013-06-30 | $1.54B | $1.00B | 1.54 |
| 2013-03-31 | $1.57B | $0.98B | 1.60 |
| 2012-12-31 | $1.54B | $0.92B | 1.67 |
| 2012-09-30 | $1.49B | $0.90B | 1.66 |
| 2012-06-30 | $1.34B | $0.85B | 1.58 |
| 2012-03-31 | $1.38B | $0.85B | 1.61 |
| 2011-12-31 | $1.36B | $0.97B | 1.39 |
| 2011-09-30 | $1.16B | $1.05B | 1.10 |
| 2011-06-30 | $1.09B | $0.92B | 1.19 |
| 2011-03-31 | $1.07B | $0.92B | 1.16 |
| 2010-12-31 | $0.92B | $0.74B | 1.25 |
| 2010-09-30 | $0.91B | $0.71B | 1.28 |
| 2010-06-30 | $0.92B | $0.65B | 1.42 |
| 2010-03-31 | $0.94B | $0.65B | 1.45 |
| 2009-12-31 | $0.80B | $0.47B | 1.70 |
| 2009-09-30 | $0.78B | $0.50B | 1.57 |
| 2009-06-30 | $0.82B | $0.53B | 1.55 |
| 2009-03-31 | $0.77B | $0.52B | 1.47 |
| 2008-12-31 | $0.79B | $0.58B | 1.35 |
| 2008-09-30 | $0.82B | $0.62B | 1.32 |
| 2008-06-30 | $0.79B | $0.54B | 1.45 |
| 2008-03-31 | $0.87B | $0.49B | 1.79 |
| 2007-12-31 | $0.84B | $0.44B | 1.91 |
| 2007-09-30 | $0.84B | $0.43B | 1.95 |
| 2007-06-30 | $0.77B | $0.37B | 2.06 |
| 2007-03-31 | $0.87B | $0.43B | 2.02 |
| 2006-12-31 | $0.84B | $0.54B | 1.54 |
| 2006-09-30 | $0.64B | $0.59B | 1.09 |
| 2006-06-30 | $0.56B | $0.54B | 1.04 |
| 2006-03-31 | $0.45B | $0.42B | 1.07 |
| 2005-12-31 | $0.43B | $0.21B | 2.03 |
| 2005-09-30 | $0.48B | $0.21B | 2.31 |
| 2005-06-30 | $0.46B | $0.20B | 2.28 |
| 2005-03-31 | $0.42B | $0.17B | 2.42 |
| 2004-12-31 | $0.38B | $0.14B | 2.70 |
| 2004-09-30 | $0.35B | $0.13B | 2.82 |
| 2004-06-30 | $0.38B | $0.15B | 2.46 |
| 2004-03-31 | $0.36B | $0.11B | 3.43 |
| 2003-12-31 | $0.33B | $0.08B | 4.00 |
| 2003-09-30 | $0.36B | $0.08B | 4.30 |
| 2003-06-30 | $0.35B | $0.08B | 4.60 |
| 2003-03-31 | $0.32B | $0.07B | 4.88 |
| 2002-12-31 | $0.30B | $0.06B | 5.30 |
| 2002-09-30 | $0.28B | $0.05B | 5.28 |
| 2002-06-30 | $0.27B | $0.06B | 4.70 |
| 2002-03-31 | $0.24B | $0.05B | 5.03 |
| 2001-12-31 | $0.24B | $0.05B | 4.94 |
| 2001-09-30 | $0.22B | $0.05B | 4.33 |
| 2001-06-30 | $0.19B | $0.06B | 3.16 |
| 2001-03-31 | $0.10B | $0.03B | 3.44 |
| 2000-03-31 | $0.05B | $0.02B | 3.23 |
| 1999-03-31 | $0.06B | $0.02B | 2.93 |
| 1998-03-31 | $0.07B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |